Skip to main content
Premium Trial:

Request an Annual Quote

Arima Genomics, Basepair to Integrate 3D Genome Analysis Technology

NEW YORK – Arima Genomics said Thursday that it has formed a partnership with Basepair, a startup maker of cloud-based genomic analysis software, for bioinformatics analysis of 3D genomic data.

Arima, a 2015 spinout from the University of California, San Diego, will integrate its Arima-SV bioinformatics pipeline with Basepair's web portal to allow researchers to upload standard sequencing files for quick identification of structural variants. The system features a graphical user interface for point-and-click uploading.

"This partnership brings our customers more bioinformatics options and enables those without bioinformatics support to understand their data with an easy-to-use analysis tool," Anthony Schmitt, senior VP of science at Arima, said in a statement.

"Basepair offers a range of automated pipelines for next-generation sequencing analysis and looks forward to enabling Arima's customers with faster and easier analysis of 3D genomics data," said Amit Sinha, founder of Basepair, which is headquartered in New York.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.